$GENB
Generate Biomedicines, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Generate Biomedicines, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is GENB down today? It is at $10.05, -3.09% on the day and -3.09% pre-market, and our scanner flagged it 166 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment GENB spikes, and full due diligence on GENB — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $GENB 166 times in the last 30 days. Create a free account to track $GENB, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on GENB from our scanner (live price and day move above). Our scanner has fired 5 unusual-volume and momentum alerts on GENB today, peaking at 7.5x its normal volume.
Likely catalystGenerate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business UpdateReported Zealand Pharma collaboration provides $30 million upfront, $35 million in early preclinical milestones and nearly $1.2 billion in total potential milestones, plus tiered royaltiesReported Cash, cash equivalents, and marketable securities of $404.2 million as of Sept. 30, 2026Reported General and administrative expenses were $13.5 million for the quarter ended Sept. 30, 2026, compared with $10.3 million for the same period in 2025. The increase was driven primarily by an increase in stock-based compensation., from an SEC filing. Read it →Across every filing on file, supply equal to 18.5% of the tradeable float is in play - 18.5% has already been sold.
Recent priced share offering — a one-time sale that has already completed (not ongoing)
3,750,000 new shares
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Arnold Frances Director | Sold (automatic/other) | -11K | sold 4.9% | 220K | $185K at $16.19 | Oct 29, 26 |
Arnold Frances Director | Sold (automatic/other) | -1K | sold 0.4% | 231K | $16K at $16.00 | Sep 1, 26 |
Nally Michael Officer | Bought (open market) | +20K 0.02% of company | added 3.6% | 573K | $240K at $12.00 | Mar 4, 26 |
Afeyan Noubar Director | Acquired (grant/award) | +32.97M 25.5% of company | n/a | 13.70M | n/a | Mar 2, 26 |
Afeyan Noubar Director | Bought (open market) | +4.69M 3.6% of company | added 8.1% | 62.67M | $75.0M at $16.00 | Mar 2, 26 |
Mendillo Jane L Director | Bought (open market) | +2K | n/a | 2K | $24K at $16.00 | Mar 2, 26 |
Bancel Stephane Director | Acquired (grant/award) | +724K 0.6% of company | n/a | 724K | n/a | Mar 2, 26 |
Nally Michael Officer | Acquired (grant/award) | +658K 0.5% of company | added 40% | 2.32M | n/a | Mar 2, 26 |
Afeyan Noubar Director | Acquired (grant/award) | +32.97M 25.5% of company | n/a | 13.70M | n/a | Mar 2, 26 |
Afeyan Noubar Director | Bought (open market) | +4.69M 3.6% of company | added 8.1% | 62.67M | $75.0M at $16.00 | Mar 2, 26 |
Silvers Jason Officer | Bought (open market) | +2K | n/a | 2K | $32K at $16.00 | Mar 2, 26 |
Grous Beth Officer | Bought (open market) | +300 | n/a | 300 | $5K at $16.00 | Mar 2, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on GENB from our scanner (live price and day move above). Our scanner has fired 5 unusual-volume and momentum alerts on GENB today, peaking at 7.5x its normal volume.
GENB last traded at $10.05, down 3.09% on the day and down 3.09% pre-market. The price and chart above update live during market hours (4 AM to 8 PM ET).
The GENB Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged GENB 166 times in the last 30 days.
GENB (Generate Biomedicines, Inc. Common Stock) trades on XNAS, with a market cap of about $1.34B in the PHARMACEUTICAL PREPARATIONS sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge GENB for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$GENB discussion
Sign in to ask a question or join the discussion.